Search Results

You are looking at 191 - 200 of 2,748 items for :

  • Refine by Access: All x
Clear All
Full access

HSR20-094: Treatment Patterns, Healthcare Resource Utilization and Patient-Reported Outcomes for Patients Diagnosed With Small Cell Lung Cancer

Junji Lin, Santosh Gautam, Nan Hu, Debra Wertz, Gboyega Adeboyeje, and Sumesh Kachroo

) and patient-reported outcomes (PROs). This study describes patient characteristics, treatment patterns, HCRU and PROs for these pts in community oncology settings. Methods: Retrospective medical records data from adults diagnosed with eSCLC between 1

Full access

Introduction to the Cancer Center Cessation Initiative Working Groups: Improving Oncology Care and Outcomes by Including Tobacco Treatment

The Cancer Center Cessation Initiative Coordinating Center and Expert Advisory Panel

smokers at the time of diagnosis. 5 Although compelling data have shown that quitting smoking after a cancer diagnosis leads to better health and quality of life outcomes, a 2009 survey reported that only 38% of NCI Cancer Centers recorded smoking as a

Full access

A Survey of the National Comprehensive Cancer Network on Approaches Toward Addressing Patients’ Transportation Insecurity

Krisda H. Chaiyachati, Diana Krause, Jessica Sugalski, Evan M. Graboyes, and Lawrence N. Shulman

widened racial and income disparities in cancer treatment outcomes. 19 – 21 Although national organizations such as the National Academies of Sciences, Engineering, and Medicine have identified transportation insecurity as a key social risk factor, 22

Full access

CLO22-035: Treatment Outcome of Ruxolitinib and Decitabine Combination Chemotherapy Among Transplant Ineligible Advanced Stage Myeloproliferative Neoplasm: A Meta-analysis

Jacqueline Agustin and Ma. Rosario Irene D. Castillo

not eligible for transplant, hence chemotherapy is a frequently chosen alternative. This meta-analysis sheds light on treatment outcomes of advanced stage myeloproliferative neoplasm patients treated with combination decitabine and ruxolitinib

Full access

Testicular Cancer Survivorship

Chunkit Fung, Paul C. Dinh Jr, Sophie D. Fossa, and Lois B. Travis

long-term adverse health outcomes (AHOs) among TCS is critically important for the development of risk-stratified, evidence-based follow-up guidelines. A multi-institutional study 40 among North American TCS (median age, 37 years) after cisplatin

Full access

CLO23-025: Comparison of Outcomes Using NCCN Classification in Two Concurrent Phase III Trials in Intermediate and High Risk Prostate Cancer: Long-Term Data

Abdenour Nabid, Nathalie Carrier, Eric Vigneault, André-Guy Martin, Thu Van Nguyen, Jean-Paul Bahary, Peter Vavassis, Marc-André Brassard, Sylvie Vass, Boris Bahoric, Robert Archambault, Francois Vincent, Redouane Bettahar, Marie Duclos, Derek Wilke, and Luis Souhami

Purpose/Objective(s): To compare the magnitude of differences in outcomes between intermediate and high risk prostate cancer (IRPC – HRPC) using NCCN classification in two concurrent phase III trials performed in the same population. Materials

Full access

HSR21-051: Treatment Outcomes Among HR+/HER2- Advanced/Metastatic Breast Cancer Patients Receiving CDK 4 & 6 Inhibitors in a United States Clinical Practice Setting

Yu-Jing Huang, Paula D. Ryan, Gregory L. Price, Gebra Cuyun Carter, Kristin M. Sheffield, Emily Nash Smyth, Claudia Morato Guimaraes, Sarah Rybowski, Jonathan Rajkumar, and Lavanya Sudharshan

) patients (pts). This study examined real-world pt characteristics, select adverse events (AEs), and related outcomes of these pts. Methods: Female pts in the United States Oncology Network’s iKnowMedTM electronic health records (EHR) database were

Full access

CLO20-036: Comparative Outcomes of Patients With Locoregional Recurrent Disease Versus De Novo Locally Advanced NSCLC Treated With Definitive Therapy

Cole Friedes, Nick Mai, Wei Fu, Peijin Han, Ranh Voong, and Russell Hales

Background: Although isolated locoregional recurrence (iLR) for non-small cell lung cancer (NSCLC) is relatively common, the optimal therapy for iLR is undefined. It is feasible that patients with iLR may have equal or superior outcomes to patients

Full access

HSR23-090: Racial Differences in Outcomes of Osimertinib in Patients With EGFR-Positive Non–Small Cell Lung Cancer in a Real World US Population

Jeffrey Zhong, Jaime Abe Perez, Annie Liang Zhang, Debora Bruno, and Melinda Laine-Hsu

mortality when compared to non-Asian patients with EGFR-positive NSCLC in a real-world US population. Further research is required to determine whether this association stems from a biological or non-biological cause. Table. Outcomes between AANHPI

Full access

Does Adjuvant Bisphosphonate in Early Breast Cancer Modify the Natural Course of the Disease? A Meta-Analysis of Randomized Controlled Trials

Davide Mauri, Antonis Valachis, Nikolaos P. Polyzos, Lamprini Tsali, Dimitris Mavroudis, Vassilis Georgoulias, and Giovanni Casazza

-analysis calculations. Data Extraction and Outcomes Information recorded from each eligible trial included author names; journal; year of publication; number of centers involved; number of patients randomly assigned and analyzed per arm; years of patient